The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1337
Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Everolimus (Afinitor – Novartis) and pazopanib (Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar), two other oral multikinase inhibitors, and temsirolimus (Torisel), an IV multikinase inhibitor, were approved earlier for the same indication.1,2

TREATMENT OF RENAL CELL CANCER — The preferred treatment for renal cell cancer is surgical resection. Chemotherapy is generally used for patients whose disease has metastasized. Agents that prevent angiogenesis and tumor proliferation through inhibition of the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathways have now become the standard of care.3

EVEROLIMUS — An mTOR inhibitor, everolimus has ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer
Article code: 1337b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian